Bile Acid Articles & Analysis
6 news found
PSC is a chronic cholestatic liver disease that is caused by bile duct inflammation and fibrosis of unknown cause. The inflammation can stop the flow of bile acids and lead to liver fibrosis or liver cancer. ...
Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence Further CONSORTIUM study analysis shows that the VE303 high dose led to more robust colonization, which in turn correlated with prevention of recurrence Safety and ...
IDK® α1-Antitrypsin (K 6750, K 6760) Albumin (K 6330) IDK® EDN (K 6811, K 6821) Lysozyme (K 6900, K 6901) ß-Defensin 2 (K 6500) IDK® Bile acids (K 7878CV, K 7878W) Yellow label: IDK® Amino Extract (K 7999) Stool sample preparation system filled with the extraction buffer IDK® Amino Extract to be used to analyse the ...
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI) Only gut microbiome research program with five clinical studies demonstrating consistent ...
Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of the microbiome Research from the Phase 3 PUNCH CD3 trial on the effects of RBX2660 on deadly antimicrobial resistance genes and the restoration of bile acid composition, also will be presented. Ferring Pharmaceuticals and Rebiotix, a Ferring Company, ...
The development program includes the investigation of the influence of dysbiosis on other microbiome-modulated functions, including bile acid (BA) metabolism, which can influence C. diff colonization and colonization by antimicrobial resistant pathogens. ...